Edition:
India

Michael Erman

Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study

28 Sep 2019

About 40% of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCLC) were alive after two years, according to data presented at a medical meeting on Saturday.

Novartis blames former AveXis executives for Zolgensma data manipulation

25 Sep 2019

NEW YORK Novartis AG blamed former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million gene therapy Zolgensma, saying they either personally manipulated the data or pressured subordinates into doing so.

U.S and European regulators reviewing safety of heartburn drugs like Zantac

14 Sep 2019

U.S. and European drug regulators said on Friday they are reviewing the safety of the widely taken heartburn drug ranitidine, commonly known by the brand name Zantac, after they found traces of a probable cancer-causing impurity in some versions of the medicine.

Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion

27 Aug 2019

Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.

Novartis says it knew of Zolgensma data problems before U.S. approval

07 Aug 2019

NEW YORK Swiss Drugmaker Novartis AG on Wednesday said it knew about discrepancies in data it submitted to regulators as it sought approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed an internal investigation.

Novartis says knew about Zolgensma data problems before U.S. approval

07 Aug 2019

NEW YORK, Aug 7 Drugmaker Novartis on Wednesday acknowledged that there were discrepancies with data it had submitted to regulators for approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed its internal investigation.

U.S. FDA says some data testing Novartis' $2 million gene therapy was manipulated

07 Aug 2019

NEW YORK The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis' more than $2 million gene therapy Zolgensma was manipulated, but the agency believes the treatment should remain on the market.

Trump firms up plan to import medicines; pharma companies resist

01 Aug 2019

The Trump administration took a step Wednesday toward allowing importation of medicines from Canada, an action the president has advocated as a way to bring cheaper prescription drugs to Americans, but the pharmaceutical industry was quick to resist the move.

World News